• Associated factors in the development of osteonecrosis include poor dental health, odontogenic infection and invasive dental treatment.
• The dental management of patients with a history of bisphosphonate treatment is based around prevention and minimally traumatic treatment.
VERIFIABLE CPD PAPER
Bisphosphonate osteonecrosis of the jaws; an increasing problem for the dental practitioner Osteonecrosis of the jaws is an increasingly recognised complication of bisphosphonate therapy. Although this has gen erated a large amount of literature in the last few years, it is difficult to know how the complications associated with bisphosphonates are impacting on general dental practitioners (GDPs). Bisphosphonates are commonly prescribed in the management of osteoporosis, hypercalcemia and multiple myeloma. The risk of osteonecrosis in patients taking bisphos phonates is low but difficult to quantify. The risk associated with oral therapy is in the order of 0.01% although with parenteral therapy it may be as high as 10%. Associated factors in the development of osteonecrosis include poor dental health, odontogenic infection and invasive dental treatment. Guidelines on managing patients who are currently taking or have previously taken bisphosphonates have not yet been published in the UK. The management of patients relies on exist ing experience in managing patients with apparently similar conditions such as osteoradionecrosis. Most GDPs do not rou tinely make specific efforts to identify patients who have taken bisphosphonates, and as patients may be poor at providing such information voluntarily, it is likely that many patients are currently not identified when they attend general dental practice. The dental management of patients with a history of bisphosphonate treatment is based around prevention and minimally traumatic treatment. Failure to recognise these patients and manage them appropriately could contribute to the development of osteonecrosis, which can be very difficult to manage.
BISPHOSPHONATES
Bisphosphonates are pyrophosphate ana logues, which share a common phospho rous-carbon-phosphorous chemical core, and inhibit the resorption of bone. They are principally used in the treatment of osteoporosis, Paget's disease, multiple myeloma, bony metastatic lesions and hypercalcemia of malignancy. These compounds have been synthesised since the nineteenth century but it is only in the second half of the twentieth cen tury that their in vitro ability to inhibit the precipitation of calcium phosphate was applied clinically. In vivo they act both by inhibiting the precipitation of hydroxyapatite crystals and by direct action on osteoclasts. 1, 2 There are two classes of bisphospho nates which have different mechanisms of action on osteoclasts based on the presence or absence of a nitrogen side chain on the pyrophosphate group (Table  1) . Non-nitrogen containing bisphospho nates are taken up by the osteoclast and antagonise the cellular energy pathways leading to cell apoptosis. They therefore decrease bone breakdown by reducing osteoclast cell numbers. Nitrogen con taining bisphosphonates have a more complex pathway of action where they inhibit the HMG-CoA reductase pathway which affects the osteoclastogenesis, apoptosis and cytoskeletal dynamics, resulting in loss of adherence of osteo clasts to the surface of bone.
1 Zoledro nate has also been shown to inhibit human endothelial cell proliferation and to modulate endothelial cell adhesion and migration. 3 The antitumour effect of bisphosphonates is thought to be due to induction of tumour cell apoptosis, and inhibition of tumour cell adhesion and invasion. 4 Absorption of bisphospho nates from the gastrointestinal tract is variable, but generally poor with only 1-5% of ingested preparation becoming bioavailable. The bisphosphonates are excreted from the body unchanged, via the kidneys. About 50% of the absorbed dose is excreted whilst the remainder is absorbed onto the surface of bone, for which it has a high affinity. Oral and parenteral preparations are available with differing biovailabilities and poten cies. Generally the nitrogen containing preparations are more potent (Table 1) and are retained longer in bone.
The duration of effect of bisphospho nates extends far beyond the duration of treatment. The effect of aledronate may be evident for more than fi ve years after discontinuation of treatment and zoledronate has been shown to produce a sustained reduction in bone turnover for 12 months following administration of a single dose. 5, 6 OSTEONECROSIS OF THE JAWS Osteonecrosis means the process of bone death. Osteonecrosis of the jaws may be associated with a number of different predisposing conditions (Table 2) , and its pathophysiology varies with the pre disposing factors. Radiotherapy is asso ciated with endarteritis obliterans and consequently avascular necrosis of the bone. Bisphosphonates on the other hand are associated with increased density of bone attributable to reduced osteoclas tic function. Small vessels remain pat ent although there may be thrombosis evident histologically. It is thought to be more closely related to 'Phossy jaw' seen in phosphorous workers in the nine teenth century. 7 Osteonecrosis of the jaw bones is often asymptomatic for some time before clini cal presentation. As long as the overly ing mucosa is intact and infection is not introduced into the bone, which has lim ited healing potential, then there may be no clinical signs or symptoms of the underlying bony pathology. Risk factors for the development of clinically evident osteonecrosis include dental infection, periodontal disease, and invasive dental treatment. Presenting features include non-healing ulceration, pain, loosen ing of teeth and where present, features of infection such as swelling, erythema and a discharging sinus. A pathological fracture may be the presenting feature. In the early stages there may be no obvi ous radiological changes but later on there will be evidence of bone mottling and sequestrum formation similar to osteomyelitis. 8 Bisphosphonate associated osteonecrosis of the jaws Ulceration of the oral mucosa as a complication of oral bisphosphonate therapy was described in 1999 but this was thought to be due to direct mucosal injury. 9 Osteonecrosis associated with the use of bisphosphonates was fi rst described by Marx in 2003, 10 since which there have been a multitude of case series published. 4 The link between osteonecrosis and dental treatment is deduced from the data that between 33 and 86% of reported cases had undergone surgical treatment in the period before their diagnosis and the fact that the area of osteonecro sis was co-incident with the area of treatment. 2 Why bisphosphonates have a predilec tion for causing osteonecrosis in the jaws is not yet fully understood. It is thought to be related to the jaws being repeatedly traumatised by mastication and their exposure to the oral environment and commensal micro-organisms. 11 Many cases, however, arise appar ently spontaneously (perhaps as a result of innocuous trauma) and the dentist therefore must be vigilant to the poten tial diagnosis when examining patients with symptoms and signs which would be consistent with bisphosphonate osteonecrosis (BON).
BON affects the mandible to maxilla in a ratio of approximately 2:1, and not uncommonly both are affected. 12 Multi focal involvement has been described, mostly in the maxilla. 4 The maxilla is therefore affected more commonly than in osteoradionecrosis, as would be expected from the understanding that radiotherapy has a direct action on bone, and the mandible is more commonly irradiated than the maxilla, whereas bisphosphonates have a systemic effect.
There is as yet no agreed consensus on a method of staging and management guidelines for BON but those suggested by Ruggiero et al. are a reasonable approach until further evidence is avail able. 13 The potential difficulties in creat ing larger problem through injudicious 14 One report has also suggested an increased risk where patients have received two different parenteral preparations sequentially. 15 Although oral bisphosphonates are the most commonly prescribed form of these drugs, the incidence of BON associated with their use represent only approxi mately 11% of reported cases of BON. 16 An expert panel from the American Dental Association 17 has estimated that the risk associated with oral bisphospho nates is in the order of 0.7 per 100,000 prescribed patient years, based on data reported by pharmaceutical companies. Data from Australia suggest an inci dence of 0.01% to 0.04%, increasing to 0.09% to 0.34% in patients having den tal extractions. 18 Long term longitudinal studies will be required to elucidate more accurately the incidence, and whether specifi c bisphos phonates carry different risks. However, the sheer number of patients being pre scribed bisphosphonates suggest that this is likely to be a signifi cant problem.
Within the catchment area of our hos pital, 160,000 prescriptions have been issued for bisphosphonates in the last five years in primary and secondary care. Two hundred and eighty patients have received parenteral bisphospho nates since 2002. Although it is not pos sible to state how many patients are on oral bisphosphonates from the number of prescriptions issued, assuming every patient has received a prescription for every month since first prescribed, this suggests that at least 3,850 patients have received oral bisphosphonates. This may be a substantial underestimate.
The medical literature contains case reports and series describing over 350 cases of BON, however, to date, none have included cases from the United Kingdom. 2 In the United Kingdom adverse events following administration of prescribed drugs should be reported to the Medi cines and Healthcare products Regulatory Agency (MHRA). One hundred and fi fty eight reports of bone disorders (which includes seven reports of osteomyelitis and 58 of osteonecrosis), 13 reports of jaw disorders including pain and frac ture, and 143 reports of other oral disor ders including pain, ulceration and dental extractions have been recorded by the MHRA up to May 2006. 19 This constitutes some 8% of adverse incidents reported for bisphosphonate class drugs (Table 1) .
GDP knowledge of bisphosphonates
To obtain some information on the current knowledge of GDPs regarding bisphos phonates, we performed a postal survey of local GDPs, which asked whether they specifically asked about bisphosphonates as part of patients' medical history and whether they recommended antibiotic prophylaxis in such patients. Thirty-one replies were received from the 60 prac tices surveyed (52%).
Five out of 31 (16%) enquired spe cifically about bisphosphonates as part of the medical history. Self reporting of medication is poor, particularly for intermittent medication, and likely to be worse for medication which may only have been prescribed once as may be the case with parenteral bisphosphonates. The potentially catastrophic conse quences of developing established BON are such that we feel that general den tal practitioners should ask specifi cally about these drugs as part of their medi cal history for new patients and enquire again with returning patients. 20 The effects of bisphosphonates is known to last a long time with most cases of BON associated with oral bisphos phonates presenting after 36 months and most associated with parenteral bisphosphonates presenting after 13 months. Patients with a past history of bisphosphonate therapy should there fore be managed in the same manner as patients on current therapy.
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Recommendations for managing patients with a history of bisphosphonate therapy Whilst ultimately the incidence of BON is not known, what is clearly established is its association with poor dental health.
There are at present no consensus guidelines from British institutions on how to manage patients who are cur rently or have previously been prescribed bisphosphonates. The American Dental Association 17 and the Australian Den tal Association 18 have produced guide lines regarding the dental management of patients prescribed bisphosphonates. They all state that there is currently no Table 3 Summary of expert panel guidelines on dental management of patients
Before prescribing
Information for prescriber Consider and inform patient of risk of BON Advise patient to seek dental assessment and treatment
Information for dentist
Full dental examination
Complete all necessary dental treatment and preventative advice
After prescribing
Information for prescriber Advise regular dental attendance
Refer for assessment patents with oral symptoms consistent with BON Information for dentist Non-Surgical treatment where possible
Chlorhexidene mouthwash pre-operatively and until all wounds have healed Consider prophylactic antibiotics pre and post operatively evidence basis for the guidelines and they are based on the recommendations of panels of experts. Recommendations have also been pub lished on the use of bisphosphonates in osteoporosis and multiple myeloma on the basis of the risk of developing osteonecro sis. 21, 22 A summary of the available guide lines is presented in Table 3 .
The general consensus is that patients should, where possible, undergo a dental assessment, and any necessary treat ment should be undertaken, before com mencing on bisphosphonates. The risk of BON should be considered when discuss ing the advantages and disadvantages of bisphosphonate therapy. There is cur rently no evidence to suggest that there is any benefit in stopping bisphosphonate therapy for a period if dental treatment becomes necessary, or that there is a safe time period after bisphosphonate treat ment, when the risk of BON reduces.
The emphasis thereafter is on preven tion, including regular dental assessment and oral hygiene instruction. Treatment, where necessary, should avoid extrac tions and surgery to the gingivae.
Where required, extraction and other procedures should involve a conserva tive surgical technique and primary soft tissue closure where possible. Chlorhexi dene mouthwash is recommended before treatment and afterwards for up to two months.
Antibiotics are reserved for cases where the treatment involves signifi cant manipulation of alveolar bone and the ADA panel recommends antibiotics for two days before and 14 days after treatment, depending on the presence of other risk factors and planned surgery.
Recommended antibiotics are amoxicil lin +/-metronidazole, or clindamycin or azithromycin where penicillin allergic.
Only one out of 31 (3%) GDPs we sur veyed recommended antibiotic proph ylaxis in patients who were taking bisphosphonates. In the absence of evi dence based guidelines, particularly in the UK, it would be unreasonable to be critical of the current practice of general dental practitioners in not prescribing antibiotic prophylaxis for patients on bisphosphonates, however, it does high light a need for guidelines to be estab lished and circulated by the equivalent UK bodies.
It may be helpful if a system of patient cards, similar to those used for patients prescribed steroids, was instituted. Patients prescribed bisphosphonates could be given a card with details of their treatment to give to any treating dentist. Signs and symptoms of BON may also be listed for patients to look out for.
